AstraZeneca Pays $100M Upfront, Up to $2B Total for Jacobio’s Pan-KRAS Inhibitor JAB-23E73

AstraZeneca entered an exclusive global licensing agreement with Jacobio Pharma for JAB-23E73, a clinical-stage pan-KRAS inhibitor targeting multiple KRAS mutation subtypes.1 2 3 4

AstraZeneca gains exclusive rights to develop and commercialize JAB-23E73 outside China; both companies will jointly develop and commercialize it in China.1 2 3 4

Jacobio receives $100 million upfront payment and is eligible for up to $1.91-$1.92 billion in development and commercial milestones, plus tiered royalties on net sales outside China.1 3 4 5

JAB-23E73, developed using Jacobio's induced allosteric platform, is in Phase 1 trials in China and the U.S., showing early signs of anti-tumor activity.1 2 3 4

KRAS mutations occur in about 23% of cancer patients, driving unmet needs in pancreatic, colorectal, and lung cancers.2 3 4

Deal announced December 21-22, 2025, strengthening Jacobio's finances and AstraZeneca's KRAS oncology portfolio.1 2 4 5